Vahanian Nicholas N. 4

Accession 0001126234-19-000101

CIK 0001126234other

View on SEC.gov Company Profile

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 6:38 PM ET

Size

41.4 KB

Accession

0001126234-19-000101

Insider Transaction Report

Form 4

Period: 2019-07-31

NEWLINK GENETICS CORP(NLNK)

Vahanian Nicholas N.

Pres, Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2019-07-31+48,828→ 48,828 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (48,828 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+14,926→ 14,926 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (14,926 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+7,907→ 7,907 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (7,907 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+5,275→ 5,275 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (5,275 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,477→ 3,477 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,477 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+10,542→ 10,542 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (10,542 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+5,269→ 5,269 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (5,269 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+19,531→ 19,531 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (19,531 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+5,269→ 5,269 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (5,269 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+100,000→ 100,000 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (100,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−312,500→ 0 total
Exercise: $10.55→ Common Stock (312,500 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+25,820→ 25,820 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (25,820 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+19,531→ 19,531 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (19,531 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+7,907→ 7,907 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (7,907 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+6,158→ 6,158 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (6,158 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+19,532→ 19,532 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (19,532 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+19,532→ 19,532 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (19,532 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−126,500→ 0 total
Exercise: $7.85→ Common Stock (126,500 underlying)

Footnotes (8)

[F1]The option provided that 50% of the option grant would vest in a series of 48 successive equal monthly installments beginning on February 3, 2017 and the remaining 50% would vest upon specified performance objectives, in each case, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
[F2]Unless otherwise disclosed, the option expires ten years after the date of grant.
[F3]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F4]The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
[F5]The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
[F6]The option provided that 50% of the option grant would vest in a series of 48 successive equal monthly installments beginning on April 9, 2018 and the remaining 50% would vest upon specified performance objectives, in each case, provided that as the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
[F7]This option grant was detailed in the proxy statement and approved by the stockholders at the Annual Meeting on May 9, 2019.
[F8]The option vests as to 50% on the second anniversary of grant date, 25% on the third anniversary of grant date and the remaining 25% on the fourth anniversary of grant date.

Documents

1 file

4
wf-form4_156478547458526.xmlPrimary
FORM 4

Issuer

NEWLINK GENETICS CORP

CIK 0001126234

→

Entity typeother

Related Parties

filerCIK 0001512114

Filing Metadata

Form type: 4
Filed: Aug 1, 8:00 PM ET
Accepted: Aug 2, 6:38 PM ET
Size: 41.4 KB

View on SEC.gov